INTERCEPT Blood System for Platelets

About Cerus

Cerus Corporation is dedicated to becoming the preeminent global blood products company by safeguarding the world's blood supply through its INTERCEPT pathogen reduction technology. The company has achieved significant commercial traction with its FDA and CE-marked systems for platelets and plasma, and its U.S.-approved INTERCEPT Fibrinogen Complex. Its strategic focus is on expanding the INTERCEPT platform to all major blood components, most critically red blood cells, while driving global adoption through partnerships with blood centers and health authorities.

Therapeutic Areas